Prolia (Denosumab) Cost in California 2026

What Does Prolia (Denosumab) Actually Cost in California in 2026?

The Amgen wholesale acquisition cost (WAC) for Prolia sits at approximately $1,500 per 60 mg prefilled syringe in 2026. Because the drug is given only twice per year, the annual list-price exposure is roughly $3,000. Few California patients pay that figure out of pocket, but understanding the baseline number matters when you are comparing insurance coverage tiers, assistance programs, or compounded alternatives.

Retail pharmacy cash prices across California pharmacies cluster tightly around the WAC because denosumab lacks generic competition in the branded biologic market. Major chains including CVS, Walgreens, and Rite Aid generally quote $1,490 to $1,520 per syringe before any discount. Independent compounding pharmacies operating as FDA-registered 503A facilities charge significantly less, and that option is discussed in detail in the compounding section below.

Denosumab belongs to the RANK ligand (RANKL) inhibitor class. It is not a small-molecule drug, so standard GoodRx-style coupons provide modest reductions at best, typically cutting the price by only $50 to $150 per dose at most California pharmacies. The most effective cost-reduction tools are manufacturer assistance, Medi-Cal coverage, and commercial insurance, each addressed in its own section.

The FDA-approved Prolia label specifies 60 mg subcutaneous injection every 6 months for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, and bone loss associated with certain hormone-ablation therapies. FDA Prolia Prescribing Information

Why Is Prolia So Expensive Without Insurance?

Prolia is a fully human monoclonal antibody manufactured through cell-culture biologic processes. Biologic manufacturing costs are substantially higher than small-molecule synthesis costs. No FDA-approved biosimilar denosumab was on the California market at the start of 2026, though Jubbonti (denosumab-bbdz, Sandoz) and Wyost received FDA approvals in 2024 and biosimilar uptake is expected to grow through 2026 and 2027. FDA biosimilar approvals

Patent exclusivity and biologic complexity keep the reference product expensive. A single dose cycle costs more than a full month of most oral osteoporosis drugs. Alendronate 70 mg weekly, by comparison, costs $10 to $25 per month at California pharmacies with a GoodRx coupon. Patients who cannot tolerate oral bisphosphonates or who have documented absorption problems are the most common candidates for denosumab, which means the cost issue is not easily sidestepped by switching drug class.

The FREEDOM trial (N=7,808) published in the New England Journal of Medicine demonstrated that denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 36 months compared with placebo. FREEDOM trial, NEJM 2009 That fracture-reduction data underpins why guidelines back the drug for high-fracture-risk patients even at elevated cost.

Does Medi-Cal (California Medicaid) Cover Prolia (Denosumab)?

Medi-Cal covers denosumab for osteoporosis but requires prior authorization (PA) for most enrollees. The PA criteria generally require documentation of a dual-energy X-ray absorptiometry (DXA) T-score of -2.5 or below, or a T-score between -1.0 and -2.5 with a 10-year major osteoporotic fracture probability at or above 20% using FRAX, or a history of fragility fracture. Prescribers also typically need to document that the patient has a contraindication to or has failed oral bisphosphonate therapy, though specific criteria can vary by Medi-Cal managed care plan.

California's Medi-Cal Drug List (Medi-Cal formulary) classifies Prolia as a preferred drug with PA. Once approved, Medi-Cal members generally pay no out-of-pocket cost for the drug itself. Administration charges for the in-office injection are covered under Medi-Cal Part B-equivalent benefits. Medi-Cal formulary reference via Medicaid.gov

For patients enrolled in Medi-Cal managed care plans rather than fee-for-service Medi-Cal, the PA process runs through the individual managed care organization. Blue Shield of California Promise Health Plan, Molina Healthcare of California, and Health Net Community Solutions are among the largest Medi-Cal managed care plans in the state, and each publishes its own PA form for denosumab. Turnaround time is typically 5 to 14 business days for standard PA and 72 hours for urgent or expedited review.

Dual-eligible patients (Medicare and Medi-Cal) receive denosumab under Medicare Part B as a physician-administered injectable, with Medi-Cal as secondary payer covering the Part B 20% coinsurance. The net patient cost in that scenario is commonly $0.

Which Commercial Insurance Plans Cover Prolia in California?

Most major commercial health plans operating in California place Prolia on their specialty tier formulary, typically tier 4 or tier 5. Anthem Blue Cross of California, Blue Shield of California, Cigna, Aetna, Health Net, and Kaiser Permanente all list denosumab on their 2026 formularies, each with prior authorization requirements similar to Medi-Cal.

Standard PA requirements across commercial plans in California include:

• A DXA scan result confirming osteoporosis (T-score -2.5 or below) or osteopenia with documented high fracture risk
• Prescriber attestation that oral bisphosphonate therapy was trialed for at least 3 to 6 months or is medically contraindicated
• Diagnosis code aligning with an FDA-approved indication

After PA approval, out-of-pocket costs depend on plan design. Specialty tier copays in California range from $80 to $350 per dose before manufacturer assistance. The Amgen Assist 360 program can reduce that to $0 or as little as $5 per dose for commercially insured patients who meet income criteria, discussed below.

Kaiser Permanente members receive denosumab as an in-office injectable through Kaiser facilities. The drug cost is bundled into the office visit or administered at an infusion center, so the patient-facing cost structure differs from open-market pharmacy plans.

How Does the Amgen Savings Card Work in California?

The Amgen Assist 360 co-pay card for Prolia is available to California residents with commercial insurance (Medicare and Medicaid patients are not eligible per federal anti-kickback guidelines). Eligible patients may pay as little as $0 per dose, with Amgen covering up to $13,000 per year in out-of-pocket costs. Amgen Assist 360 program

To activate the card, the prescriber or patient enrolls at the Amgen Assist 360 portal or calls 1-888-772-6436. Enrollment takes 10 to 20 minutes and generally produces a card number usable at the first injection appointment. The card works at physician offices, specialty pharmacies, and infusion centers, which is where most California patients receive the injection.

California law does not restrict manufacturer savings card use the way some other states do, so this program is broadly accessible to commercially insured Californians. The main disqualifiers are Medicare Part D enrollment, Medi-Cal enrollment, and lack of FDA-approved commercial insurance coverage. Patients who are uninsured do not qualify for the co-pay card but may qualify for the Amgen Safety Net Foundation free-drug program, which applies income-based eligibility thresholds. Households at or below 500% of the federal poverty level are a common cutoff for free-drug programs, though Amgen adjusts criteria periodically.

Is Compounded Denosumab Legal in California?

Compounded denosumab from a licensed 503A pharmacy is legal in California under both federal and state law, with important limitations. The California State Board of Pharmacy licenses and inspects 503A compounding pharmacies, and federal law under the Drug Quality and Security Act (DQSA) governs the framework under which they operate. FDA 503A compounding framework

A 503A pharmacy may compound denosumab for an individual patient based on a valid prescription from a licensed California prescriber, as long as the compounded preparation is not essentially a copy of an FDA-approved commercially available drug. This "essentially a copy" restriction is the primary legal nuance. Some compounding pharmacies formulate denosumab at concentrations, volumes, or with excipients that differ from the commercial product to satisfy this requirement, and legal analysis of a specific preparation should come from the prescriber and pharmacist involved in that individual case.

The cost advantage is real. While branded Prolia runs ~$1,500 per dose, compounded denosumab from 503A pharmacies is often available in the range of $200 to $400 per preparation, depending on the pharmacy. Some telehealth-adjacent compounding pharmacies have listed prices as low as the $0 figure cited in some competitor analyses, which likely reflects a subscription or bundled-care model rather than a true zero-cost preparation.

Patients considering compounded denosumab should confirm the following with their prescriber:

• The pharmacy holds an active California Board of Pharmacy license (verifiable at the BreEZe database)
• The compounding pharmacy performs sterility and potency testing on each lot
• The prescriber has reviewed the patient's renal function, calcium levels, and dental health before initiating therapy, consistent with the FDA-approved labeling requirements

Compounded biologics carry analytical and stability uncertainties that branded biologics do not. FDA-approved biosimilars like Jubbonti offer a middle path: regulated manufacturing quality at a price discount to the reference product, though biosimilar market penetration in California varies by pharmacy network.

Can You Get a Prolia (Denosumab) Prescription via Telehealth in California?

Yes. California law permits telehealth prescribing of denosumab. Under California Business and Professions Code Section 2290.5, a valid patient-physician relationship can be established via synchronous audio-video telehealth encounter, satisfying the prescribing requirements for a controlled-substance-free medication like denosumab. California telehealth statute overview via CMS

A telehealth visit for Prolia typically covers:

• Review of the DXA scan (the patient uploads or the clinic retrieves results electronically)
• FRAX fracture risk calculation
• Medical history review (renal function, calcium, vitamin D status, dental health)
• Discussion of injection site and administration logistics

The injection itself requires an in-person setting, either a primary care office, endocrinologist, rheumatologist, or infusion center. Telehealth handles the evaluation and prescription; a separate in-person encounter handles the subcutaneous injection. Some California HealthRX patients use telehealth to establish care, obtain a prescription, and then coordinate injection at a local clinic or receive a home-nurse visit for administration.

California's telehealth parity laws require commercial insurers to reimburse telehealth visits at rates comparable to in-person visits for covered services, which reduces the incremental cost of using a telehealth pathway versus a traditional office visit.

What Is the Most Cost-Effective Path to Denosumab in California?

The answer depends on insurance status and fracture-risk profile.

Commercially insured patients will almost always find the Amgen co-pay card route cheapest after insurance covers the bulk of the cost. Total patient annual expenditure frequently lands at $0 to $60 for two doses per year.

Medi-Cal enrollees should pursue prior authorization through their managed care plan. When approved, out-of-pocket cost is $0. A prescriber experienced with Medi-Cal PA documentation is the biggest variable in approval speed. Rejection rates at first submission are lower when the PA package includes the DXA report, FRAX score printout, and a clear contraindication or failure note for oral bisphosphonates.

Uninsured patients have two realistic options: the Amgen Safety Net Foundation (income-qualified, free drug) or a licensed 503A compounding pharmacy. The 503A route is accessible to any patient with a valid California prescription, requires no income verification, and can reduce per-dose cost to roughly $200 to $400.

Medicare patients receive denosumab under Part B, not Part D. The drug is administered and billed by the provider's office. Medicare pays 80% of the allowed amount; the remaining 20% is the patient's responsibility unless a Medigap plan or Medi-Cal secondary coverage applies. The Amgen co-pay card does not apply to Medicare beneficiaries.

The table below summarizes estimated 2026 annual out-of-pocket costs across coverage scenarios for a California patient receiving two Prolia doses per year.

| Coverage Scenario | Estimated Annual Patient Cost | |---|---| | Commercial insurance plus Amgen co-pay card | $0 to $60 | | Medi-Cal (with approved PA) | $0 | | Medicare Part B (no supplement) | ~$600 (20% of allowed amount) | | Medicare Part B plus Medigap Plan G | $0 after deductible | | Medicare plus Medi-Cal (dual eligible) | $0 | | Uninsured, Amgen Safety Net Foundation | $0 (income-qualified) | | Uninsured, 503A compounded denosumab | ~$400 to $800/year | | Uninsured, branded cash pay | ~$3,000/year |

The Clinical Evidence Behind the Cost: Is Prolia Worth the Price?

Cost analysis benefits from a clear efficacy anchor. The FREEDOM trial (N=7,808 postmenopausal women with osteoporosis, 36-month duration) remains the foundational dataset. Denosumab reduced new vertebral fractures by 68% (7.2% placebo vs. 2.3% denosumab; P<0.001), hip fractures by 40% (1.2% vs. 0.7%; P<0.001), and nonvertebral fractures by 20% (8.0% vs. 6.5%; P<0.001). FREEDOM trial, NEJM 2009

The American Association of Clinical Endocrinologists (AACE) 2020 clinical practice guidelines for postmenopausal osteoporosis list denosumab as a first-line agent for patients at very high fracture risk, defined as a T-score below -3.0 or a prior fragility fracture at the hip or spine. AACE osteoporosis guidelines

The Endocrine Society similarly supports denosumab as a first- or second-line option depending on fracture risk tier. Their 2019 clinical practice guideline states: "We suggest denosumab as an alternative to bisphosphonates in postmenopausal women with osteoporosis at moderate to high fracture risk, particularly those who cannot tolerate oral bisphosphonates or have impaired renal function." Endocrine Society clinical practice guideline

One clinical detail with direct cost implications: stopping denosumab without transitioning to a bisphosphonate can cause rapid bone mineral density loss and rebound vertebral fractures within 12 to 24 months of the last dose. This rebound risk means patients should not stop denosumab due to cost without a medically supervised transition plan. A prescriber who initiates denosumab should have an explicit strategy for long-term management, whether that means continued denosumab, transition to zoledronic acid (annual IV infusion), or sequential therapy. Rebound fracture data, JBMR

Understanding the Injection Process and Administration Costs

Prolia is administered as a 60 mg subcutaneous injection, typically given in the abdomen, upper thigh, or upper arm, in a clinical setting. The injection itself takes under 5 minutes. Administration charges vary across California.

In a primary care or endocrinology office, the CPT code for the injection (96372, therapeutic/prophylactic injection, subcutaneous or intramuscular) adds $20 to $60 to the visit cost before insurance adjustments. Patients with established care may receive the injection during a brief nurse visit, avoiding a full evaluation and management charge. Freestanding infusion centers may charge an infacility fee of $80 to $200 for the administration encounter.

Medicare covers the drug under Part B (buy-and-bill model) and reimburses the administration code separately. California commercial plans follow similar structures but reimbursement rates vary by contract.

Vitamin D and calcium status should be assessed before the first injection. The FDA prescribing information recommends correcting hypocalcemia before initiating denosumab. A baseline 25-hydroxyvitamin D level, basic metabolic panel, and dental exam are standard pre-treatment steps. Lab costs for this pre-treatment workup run $50 to $150 without insurance and are typically covered under preventive or diagnostic benefits for insured patients.

Monitoring Requirements and Their Cost Implications

Patients on denosumab require periodic monitoring that generates its own cost stream. Standard monitoring for a California patient includes:

• DXA bone density scan every 1 to 2 years (CPT 77080, reimbursed at roughly $130 to $250 in California under Medicare rates; commercial rates vary)
• Serum calcium measurement approximately 2 weeks after each injection
• Annual 25-hydroxyvitamin D level
• Dental evaluation before initiation and periodically during therapy (osteonecrosis of the jaw is a rare but documented risk)

The calcium and vitamin D supplementation often prescribed alongside denosumab adds a small but real monthly cost. Standard supplementation of 1,000 to 1 to 200 mg calcium and 800 to 2 to 000 IU vitamin D3 daily runs $10 to $20 per month in California.

Atypical femur fractures and osteonecrosis of the jaw are the two most clinically significant adverse events. Both are rare at the doses and durations used for osteoporosis. Long-term FREEDOM extension data showed that the rate of osteonecrosis of the jaw across up to 10 years of therapy remained below 1%. FREEDOM extension data, Osteoporosis International